pharmaphorum

MARCH 10, 2022

Mallinckrodt’s liability problems in the US have been lightened slightly, after it agreed a $260 million deal to resolve allegations of Medicare rebate fraud and payment of illegal kickbacks. The Ireland-domiciled company was accused of illegally paying smaller drug rebates to Medicaid than were due, as well as using a charitable foundation to cover co-pays for its Acthar Gel (corticotropin) epilepsy treatment – which is not allowed under US law.

104

104

NICE

MARCH 10, 2022

Following the launch of the international strategy for NICE , I’m keen to reflect on the importance of international collaborations and partnerships. The COVID-19 pandemic, the extraordinary pace of healthcare innovation, rising costs and the need for accessible, reliable, up-to-date information, are just a few examples highlighting the importance of shared learning on a global scale.

52

52

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials. The Netherlands-based biotech, which is putting together a pipeline of genetic modifier drugs for cancer and rare diseases, said the new funding would also allow it to double its headcount to add clinical capabilities and move to a larger facility.

Immunization 98

Immunization 98

Outsourcing Pharma

MARCH 10, 2022

The pharma company is evaluating its Paxlovid oral treatment, intended for high-risk patients who have tested positive for the virus, in pediatric subjects.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 10, 2022

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the field, biologics have remained largely untapped. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. “Biologics have revolutionised treatments for several serious diseases, some of which had no therapeutic alternatives until now,” says Antonio Magnelli, head of the Chiesi

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunization 96

Outsourcing Pharma

MARCH 10, 2022

Patient-centric company Belong.life has developed an app designed to inform cancer research by offering a holistic view of the lives of people with cancer.

52

52

Pharma Times

MARCH 10, 2022

Certain areas in the UK have been experiencing a significant increase in COVID-19 cases in recent days

47

47

pharmaphorum

MARCH 10, 2022

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its aim of €3 billion in peak sales for the drug. Nubeqa is already making headway in the market as a treatment for non-metastatic, castration resistant prostate cancer (nmCRPC), with sales of €219 million last year, but will need to expand into new forms of the disease if it is to meet its commerc

Labelling 81

Labelling Chemotherapy 81

Pharma Times

MARCH 10, 2022

The government’s planned ‘Road to Recovery’ will have a new focus on prevention

43

43

pharmaphorum

MARCH 10, 2022

Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B. With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms.

Vaccines 52

Vaccines Immunization 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MARCH 10, 2022

Consumer electronics giant LG has made a big foray into the digital health arena via a partnership with US telehealth player Amwell. The two companies say they intend to develop “device-based service solutions designed to make it easier for patients to access care, whether in a hospital or at home.” South Korean LG – which makes a huge range of devices from TVs and refrigerators to cell phones and computer monitors – will create devices that will be able to host services from Amwell&

Hospitals 72

Hospitals 72